FHTX

Foghorn Therapeutics Inc. (NASDAQ:FHTX) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Cambridge, Massachusetts. The company went public in October 2020 and focuses on discovering and developing innovative cancer treatments by targeting the chromatin regulatory system, a fundamental cellular mechanism that controls gene expression. Foghorn has built its drug discovery efforts around a proprietary platform called Gene Traffic Control, which identifies vulnerabilities in cancer cells that can be exploited with targeted therapies.